MedicaidDocumentationHigh impact
Zepbound for Obstructive Sleep Apnea - Guidance
Alaska Medicaid·AK · Sleep Medicine, Pulmonology, Bariatric Surgery +2 more·Program Update
Effective date
Jul 17, 2026
We identified it
Jul 18, 2026
Summary
Alaska Medicaid is clarifying coverage criteria for Zepbound (tirzepatide) when prescribed for Obstructive Sleep Apnea (OSA). Claims must be accompanied by documented sleep studies showing an Apnea-Hypopnea Index (AHI) ≥15 events/hour in patients with BMI ≥30 kg/m². Claims submitted without qualifying sleep study documentation will be subject to recoupment. Additionally, Zepbound prescribed for weight management alone remains non-covered per existing Alaska Medicaid policy.
Action Required
Effective immediately (7/17/2026): Billing team must implement verification protocols to ensure all Zepbound claims for OSA diagnosis include attached sleep study documentation meeting AASM guidelines with AHI ≥15 events/hour before submission. Update claim submission checklist in billing system to flag missing sleep study records. Providers must verify patient BMI ≥30 kg/m² is documented in the medical record. Establish internal audit process to review Zepbound claims before transmission to Alaska Medicaid. Educate all clinical staff that Zepbound prescribed for weight management only (without qualifying OSA diagnosis and sleep study) will be denied and subject to recoupment. Implement denial management protocol for claims rejected due to missing or non-qualifying sleep study documentation.